152 related articles for article (PubMed ID: 11495587)
1. Development of serine protease inhibitors displaying a multicentered short (<2.3 A) hydrogen bond binding mode: inhibitors of urokinase-type plasminogen activator and factor Xa.
Verner E; Katz BA; Spencer JR; Allen D; Hataye J; Hruzewicz W; Hui HC; Kolesnikov A; Li Y; Luong C; Martelli A; Radika K; Rai R; She M; Shrader W; Sprengeler PA; Trapp S; Wang J; Young WB; Mackman RL
J Med Chem; 2001 Aug; 44(17):2753-71. PubMed ID: 11495587
[TBL] [Abstract][Full Text] [Related]
2. Exploiting subsite S1 of trypsin-like serine proteases for selectivity: potent and selective inhibitors of urokinase-type plasminogen activator.
Mackman RL; Katz BA; Breitenbucher JG; Hui HC; Verner E; Luong C; Liu L; Sprengeler PA
J Med Chem; 2001 Nov; 44(23):3856-71. PubMed ID: 11689072
[TBL] [Abstract][Full Text] [Related]
3. A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site.
Katz BA; Elrod K; Luong C; Rice MJ; Mackman RL; Sprengeler PA; Spencer J; Hataye J; Janc J; Link J; Litvak J; Rai R; Rice K; Sideris S; Verner E; Young W
J Mol Biol; 2001 Apr; 307(5):1451-86. PubMed ID: 11292354
[TBL] [Abstract][Full Text] [Related]
4. Engineering inhibitors highly selective for the S1 sites of Ser190 trypsin-like serine protease drug targets.
Katz BA; Sprengeler PA; Luong C; Verner E; Elrod K; Kirtley M; Janc J; Spencer JR; Breitenbucher JG; Hui H; McGee D; Allen D; Martelli A; Mackman RL
Chem Biol; 2001 Nov; 8(11):1107-21. PubMed ID: 11731301
[TBL] [Abstract][Full Text] [Related]
5. Elaborate manifold of short hydrogen bond arrays mediating binding of active site-directed serine protease inhibitors.
Katz BA; Elrod K; Verner E; Mackman RL; Luong C; Shrader WD; Sendzik M; Spencer JR; Sprengeler PA; Kolesnikov A; Tai VW; Hui HC; Breitenbucher JG; Allen D; Janc JW
J Mol Biol; 2003 May; 329(1):93-120. PubMed ID: 12742021
[TBL] [Abstract][Full Text] [Related]
6. 2-(2-Hydroxy-3-alkoxyphenyl)-1H-benzimidazole-5-carboxamidine derivatives as potent and selective urokinase-type plasminogen activator inhibitors.
Mackman RL; Hui HC; Breitenbucher JG; Katz BA; Luong C; Martelli A; McGee D; Radika K; Sendzik M; Spencer JR; Sprengeler PA; Tario J; Verner E; Wang J
Bioorg Med Chem Lett; 2002 Aug; 12(15):2019-22. PubMed ID: 12113832
[TBL] [Abstract][Full Text] [Related]
7. Structural basis for selectivity of a small molecule, S1-binding, submicromolar inhibitor of urokinase-type plasminogen activator.
Katz BA; Mackman R; Luong C; Radika K; Martelli A; Sprengeler PA; Wang J; Chan H; Wong L
Chem Biol; 2000 Apr; 7(4):299-312. PubMed ID: 10779411
[TBL] [Abstract][Full Text] [Related]
8. Recruiting Zn2+ to mediate potent, specific inhibition of serine proteases.
Katz BA; Luong C
J Mol Biol; 1999 Sep; 292(3):669-84. PubMed ID: 10497030
[TBL] [Abstract][Full Text] [Related]
9. Contribution of multicentered short hydrogen bond arrays to potency of active site-directed serine protease inhibitors.
Katz BA; Spencer JR; Elrod K; Luong C; Mackman RL; Rice M; Sprengeler PA; Allen D; Janc J
J Am Chem Soc; 2002 Oct; 124(39):11657-68. PubMed ID: 12296731
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and activity of a novel series of factor Xa inhibitors: optimization of arylamidine groups.
Phillips G; Guilford WJ; Buckman BO; Davey DD; Eagen KA; Koovakkat S; Liang A; McCarrick M; Mohan R; Ng HP; Pinkerton M; Subramanyam B; Ho E; Trinh L; Whitlow M; Wu S; Xu W; Morrissey MM
J Med Chem; 2002 Jun; 45(12):2484-93. PubMed ID: 12036356
[TBL] [Abstract][Full Text] [Related]
11. Design and quantitative structure-activity relationship of 3-amidinobenzyl-1H-indole-2-carboxamides as potent, nonchiral, and selective inhibitors of blood coagulation factor Xa.
Matter H; Defossa E; Heinelt U; Blohm PM; Schneider D; Müller A; Herok S; Schreuder H; Liesum A; Brachvogel V; Lönze P; Walser A; Al-Obeidi F; Wildgoose P
J Med Chem; 2002 Jun; 45(13):2749-69. PubMed ID: 12061878
[TBL] [Abstract][Full Text] [Related]
12. Species specificity of amidine-based urokinase inhibitors.
Klinghofer V; Stewart K; McGonigal T; Smith R; Sarthy A; Nienaber V; Butler C; Dorwin S; Richardson P; Weitzberg M; Wendt M; Rockway T; Zhao X; Hulkower KI; Giranda VL
Biochemistry; 2001 Aug; 40(31):9125-31. PubMed ID: 11478879
[TBL] [Abstract][Full Text] [Related]
13. Preparation, characterization, and the crystal structure of the inhibitor ZK-807834 (CI-1031) complexed with factor Xa.
Adler M; Davey DD; Phillips GB; Kim SH; Jancarik J; Rumennik G; Light DR; Whitlow M
Biochemistry; 2000 Oct; 39(41):12534-42. PubMed ID: 11027132
[TBL] [Abstract][Full Text] [Related]
14. 3D-QSAR CoMFA studies on trypsin-like serine protease inhibitors: a comparative selectivity analysis.
Bhongade BA; Gouripur VV; Gadad AK
Bioorg Med Chem; 2005 Apr; 13(8):2773-82. PubMed ID: 15781388
[TBL] [Abstract][Full Text] [Related]
15. Dissecting and designing inhibitor selectivity determinants at the S1 site using an artificial Ala190 protease (Ala190 uPA).
Katz BA; Luong C; Ho JD; Somoza JR; Gjerstad E; Tang J; Williams SR; Verner E; Mackman RL; Young WB; Sprengeler PA; Chan H; Mortara K; Janc JW; McGrath ME
J Mol Biol; 2004 Nov; 344(2):527-47. PubMed ID: 15522303
[TBL] [Abstract][Full Text] [Related]
16. Identification of orally bioavailable, non-amidine inhibitors of Urokinase Plasminogen Activator (uPA).
West CW; Adler M; Arnaiz D; Chen D; Chu K; Gualtieri G; Ho E; Huwe C; Light D; Phillips G; Pulk R; Sukovich D; Whitlow M; Yuan S; Bryant J
Bioorg Med Chem Lett; 2009 Oct; 19(19):5712-5. PubMed ID: 19703768
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of 4,5-disubstituted-thiophene-2-amidines as potent urokinase inhibitors.
Rudolph MJ; Illig CR; Subasinghe NL; Wilson KJ; Hoffman JB; Randle T; Green D; Molloy CJ; Soll RM; Lewandowski F; Zhang M; Bone R; Spurlino JC; Deckman IC; Manthey C; Sharp C; Maguire D; Grasberger BL; DesJarlais RL; Zhou Z
Bioorg Med Chem Lett; 2002 Feb; 12(3):491-5. PubMed ID: 11814826
[TBL] [Abstract][Full Text] [Related]
18. Identification of novel binding interactions in the development of potent, selective 2-naphthamidine inhibitors of urokinase. Synthesis, structural analysis, and SAR of N-phenyl amide 6-substitution.
Wendt MD; Rockway TW; Geyer A; McClellan W; Weitzberg M; Zhao X; Mantei R; Nienaber VL; Stewart K; Klinghofer V; Giranda VL
J Med Chem; 2004 Jan; 47(2):303-24. PubMed ID: 14711304
[TBL] [Abstract][Full Text] [Related]
19. Design of potent selective zinc-mediated serine protease inhibitors.
Katz BA; Clark JM; Finer-Moore JS; Jenkins TE; Johnson CR; Ross MJ; Luong C; Moore WR; Stroud RM
Nature; 1998 Feb; 391(6667):608-12. PubMed ID: 9468142
[TBL] [Abstract][Full Text] [Related]
20. 4-Aminoarylguanidine and 4-aminobenzamidine derivatives as potent and selective urokinase-type plasminogen activator inhibitors.
Spencer JR; McGee D; Allen D; Katz BA; Luong C; Sendzik M; Squires N; Mackman RL
Bioorg Med Chem Lett; 2002 Aug; 12(15):2023-6. PubMed ID: 12113833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
